Surgeons urge better labelling for demineralised bone
This article was originally published in Clinica
Executive Summary
Demineralised bone products should include information on their labels about their osteoinductive capability, the American Academy of Orthopedic Surgeons (AAOS) contends. "Evolving research suggests that not all bone products have the same abilities to induce bone formation," the organisation said in a recent letter to acting FDA commissioner Bernard Schwetz.
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.